

Alpha-adrenergic mRNA subtype expression in the human nasal turbinate

[Expression du sous-type d'ARN messenger alpha-adrénergique dans le cornet nasal humain]

Mark Stafford-Smith MD,* Raquel Bartz MD,*† Katrina Wilson,* James N. Baraniuk MD,§
Debra A. Schwinn MD*†‡

Purpose: Alpha-adrenergic receptor (AR) agonist drugs (e.g., epinephrine) are commonly used for upper airway procedures, to shrink the mucosa, retard absorption of local anesthetic agents, and improve visualization by limiting hemorrhage. Decongestant therapy often also includes α AR agonist agents, however overuse of these drugs (e.g., oxymetazoline) can result in chronic rhinitis and rebound increases in nasal secretion. Since current decongestants stimulate α ARs non-selectively, characterization of α AR subtype distribution in human airway (nasal turbinate) offers an opportunity to refine therapeutic targets while minimizing side-effects. We, therefore, investigated α AR subtype expression in human nasal turbinate within epithelial, duct, gland, and vessel cells using *in situ* hybridization.

Methods: Since sensitive and specific anti-receptor antibodies and highly selective α AR subtype ligands are currently unavailable, *in situ* hybridization was performed on sections of three human nasal turbinate samples to identify distribution of α AR subtype mRNA. Subtype specific 35 S-labelled mRNA probes were incubated with nasal turbinate sections, and protected fragments remaining after RNase treatment analyzed by light and darkfield microscopy.

Results: In non-vascular tissue α_{1d} AR mRNA predominates, whereas notably the α_{2c} is the only α AR subtype present in the sinusoids and arteriovenous anastomoses.

Conclusion: Combined with the current understanding that AR-mediated constriction of nasal sinusoids underpins decongestant therapies that minimize secretions and shrink tissues for airway procedures, these findings suggest that α_{2c} AR subtypes provide a novel selective target for decongestant therapy in humans.

Objectif: Les médicaments agonistes des récepteurs alpha-adrénergiques (AR) (par ex., l'épinéphrine) sont communément utilisés lors des interventions sur les voies aériennes supérieures, afin de rétrécir la muqueuse, de retarder l'absorption d'agents anesthésiques locaux et d'améliorer la visualisation en limitant l'hémorragie. Un traitement décongestionnant inclut également souvent des agents agonistes α AR; toutefois, la surutilisation de ces médicaments (par ex., l'oxymétazoline) peut engendrer une rhinite chronique et l'augmentation rebond des sécrétions nasales lors de la cessation du traitement. Puisque les décongestionnants actuels stimulent les α AR de manière non-sélective, la caractérisation de la distribution des sous-types d' α AR dans les voies aériennes de l'homme (cornet nasal) offre la possibilité de perfectionner les cibles thérapeutiques tout en minimisant les effets secondaires. C'est pourquoi nous avons examiné l'expression des sous-types d' α AR au niveau du cornet nasal humain dans les cellules épithéliales, du canal, des glandes et des vaisseaux, à l'aide d'une hybridation *in situ*.

Méthode : Étant donné que des anticorps anti-récepteurs sensibles et spécifiques ainsi que des ligands très sélectifs des sous-types d' α AR sont disponibles actuellement, l'hybridation *in situ* a été effectuée sur des sections de trois échantillons de cornet nasal humain afin d'identifier la distribution d'ARN messenger des sous-types d' α AR. Des sondes d'ARN messenger marquées au 35 S et spécifiques au sous-type ont été incubées avec des sections de cornet nasal, et les fragments protégés restants après le traitement à la ribonucléase ont été analysés par microscopie optique et sur fond noir.

Résultats : Dans les tissus non-vasculaires, l'ARN messenger AR α_{1d} est prédominant, alors que le α_{2c} est notablement le seul sous-type d' α AR présent dans les sinusoides et les anastomoses artérioveineuses.

CAN J ANESTH 2007 / 54: 7 / pp 549-555

From the Departments of Anesthesiology,* Pharmacology/Cancer Biology, & Medicine (Pulmonary and Cardiology),† and Surgery,‡ Duke University Medical Center, Durham, North Carolina; and the Departments of Medicine and Pediatrics,§ Georgetown University, Washington, DC, USA.

Address correspondence to: Dr. Mark Stafford-Smith, Department of Anesthesiology, Duke University Medical Center, Box 3094, DUMC, Durham, NC 27710, USA. Phone: 919-681-5046; Fax: 919-681-8993; E-mail: staff002@mc.duke.edu

Funding: This study was funded in part by NIH grant #HL49103 (DAS) and an educational grant from Proctor & Gamble. Tissue was provided by Drs. Rasmussen-Ortega and Stephen B. Liggett.

Accepted for publication February 16, 2007.

Revision accepted April 9, 2007.

Conclusion : On considère maintenant que la constriction des sinus nasaux médiée par AR est à la base des thérapies de décongestion qui minimisent les sécrétions et rapetissent les tissus lors des interventions sur les voies aériennes. Ces résultats suggèrent donc que les sous-types d'AR α_{2c} fournissent une nouvelle cible sélective pour les traitements de décongestion chez les humains.

ALPHA-ADRENERGIC receptors (α ARs) are commonly used for upper airway procedures, to shrink the mucosa, retard absorption of local anesthetic agents, and improve visualization by limiting hemorrhage, and also play a key role in the pharmacologic treatment of nasal congestion, rhinorrhea, and epistaxis. Stimulation of α -receptors on the nasal erectile apparatus leads to constriction of arteriovenous anastomoses and collapse of venous sinusoids (Figure 1). The result is a decrease in the thickness of the nasal mucosa and so an increase in the nasal cross-sectional area of airflow within the bony confines of the nostrils. These effects are mediated *in vivo* by the sympathetic innervation, and therapeutically by oral and topical sympathomimetics. Effects on epithelial cell ciliary function and glandular exocytosis have also been reported.¹ Withdrawal of sympathetic effects leads to vasodilation of the arteriovenous anastomoses and engorgement of the venous sinusoids. The result is thickening of the nasal mucosa, reduction of cross-sectional area for airflow, and nasal obstruction. Prolonged use of topical sympathomimetics such as oxymetazoline and zylometazoline may lead to rebound vasodilation, ciliary dysfunction, and increased glandular secretion in the condition of *rhinitis medicamentosa*.²⁻⁶

Nasal α ARs have been described previously. However, the specific α_1 subtypes (α_{1a} , α_{1b} , α_{1d}) and α_2 subtypes (α_{2a} - formerly α_2C10 , α_{2b} - formerly α_2C2 , α_{2c} - formerly α_2C4) that are present and their differential distribution on the epithelium, submucosal glands, arteriovenous anastomoses, post-capillary venules that regulate vascular permeability and leukocyte infiltration, and venous sinusoids have not been determined.⁷⁻⁹ Currently available partially selective α_1 - and α_2 -agonists and endogenous norepinephrine are nonselective for these receptors. In addition, α AR subtype distribution is remarkably heterogenous among cell types in different tissues and mammalian species.¹⁰⁻¹³ We hypothesize that understanding the distribution of each receptor subtype on nasal tissues may lead to more specific decongestant targets capable of providing benefit while minimizing worrisome side-effects.




FIGURE 1 Diagrammatic representation of nasal turbinate cytoarchitecture. The nasal turbinates have concentric epithelial, superficial vascular, submucosal gland, and deep erectile tissues. Dilation of the venous sinusoids increases the thickness of the mucosa and decreases the cross-sectional area of airflow (left half of diagram). Vasoconstriction of the arteriovenous anastomoses and myoepithelial cells of the sinusoidal walls cause sinusoid collapse, thinning of the mucosa, and an increase in the cross-sectional area of airflow (right half of diagram).

Identifying cell specific distribution of α AR subtypes within nasal tissue should facilitate novel pharmacologic targeting directed at the common and vexing problem of nasal decongestion. Because highly subtype specific antibodies for α AR subtypes remain unavailable, we examined α AR subtype distribution using *in situ* hybridization on human nasal turbinate tissue.

Materials and methods

Nasal turbinate tissue preparation and detection of α AR subtype mRNA

Institutional Review Board (IRB) approval and individual patient consent was obtained for access to explanted nasal turbinate tissue from three individuals undergoing endoscopic nasal surgery; in addition, IRB approval was obtained at the institution where laboratory studies were performed. Tissue samples were immediately placed in liquid nitrogen and stored at -70°C . Ten μm horizontal frozen sections were cut on a cryostat (Leitz Kryostat 1720 digital, Wetzlar, Germany) using a -20°C block, thaw mounted onto sialylated microscope slides, and stored at -70°C with desiccant until further use. Radiolabelled single strand-

ed sense (control) and antisense (specific) RNA probes were made using linearized cDNA constructs, [³⁵S]- α UTP (Dupont, NEN, Boston, MA, USA) and either SP6 or T7 RNA polymerase, as previously described; mRNA probes and controls for *in situ* experiments have been previously validated in our laboratory.¹²⁻¹⁴

In situ hybridization

Frozen slide mount sections were warmed to room temperature then rinsed for five minutes with 2 \times SSC (1 \times SSC = 0.15M NaCl, 0.04M Na citrate, pH 7.2). No permeabilization or prehybridization steps were performed. Hybridization buffer (0.02M DTT, 1x Denhart's solution (Sigma, St. Louis, MO, USA), 1 mg·mL⁻¹ salmon sperm DNA (Sigma) heated to 80°C before use, 50 μ g·mL⁻¹ transfer RNA (Sigma), 2 \times SSC, 50% formamide, 9% dextran sulfate), and 5000–7000 cpm· μ L⁻¹ linearized radiolabelled probe were applied to the slides. The slides were then incubated at 50°C overnight in sealed plastic containers lined with Whatman filter paper soaked with 50% formamide in 2 \times SSC buffer to prevent evaporation of hybridization solution. To remove non-specific binding, slides were washed as follows: sequential immersion in 1 μ L·mL⁻¹ β -mercaptoethanol solutions in 2 \times SSC (50°C, brief dip) and 50% formamide in 2 \times SSC (50°C, ten then 20 min), followed by RNase treatment using 10 μ g·mL⁻¹ RNase in 2 \times SSC (35°C, 30 min). Subsequent washes included the following: 2 \times SSC (RT, five minutes), 50% formamide in 2 \times SSC (50°C, five minutes), and 2 \times SSC (ten minutes), followed by dehydration steps using two-minute immersions each in 0.3M ammonium acetate solutions containing 50%, 70%, and finally pure 100% ethanol. After air drying for 30–60 min, slides were then dipped in warm (40°C) autoradiography emulsion (Kodak NTB2, Rochester, NY, USA) in a dark-room illuminated with a Kodak safelight #2, dried for several hours in the dark, and placed in light-sealed slide boxes with desiccant at 4°C for four weeks. After warming for 90 min to room temperature, exposed slides were developed under a safelight by sequential immersion in fresh D19 developer (Kodak) mixed 1:1 with distilled water (dH₂O at 15°C, four minutes) followed by room temperature immersions in dH₂O (20 sec), fixer (Kodak) (five minutes), and dH₂O rinses (3 \times five minutes). Slides were counterstained with hematoxylin and eosin, dehydrated in an ascending ethanol and xylene series, and coverslips added. Dry slides were examined and photographed under light and dark field microscopy using Lietz Leica (Wetzlar, Germany), WILD M420 (low power), and DMR (high power) microscopes at 100X.

TABLE I Darkfield and brightfield semiquantitative grading system to assess relative presence of α AR subtype mRNA within human nasal turbinate

| Grade | Darkfield | Brightfield |
|-------|---------------------------------------|-------------------------------|
| 0 | background | background |
| +/- | very low density of individual grains | background |
| + | low density of individual grains | individual grains |
| ++ | moderate density of grains | patterns of individual grains |
| +++ | high density grains and clusters | clusters of grains |
| ++++ | high density clusters | high density of grains |

α AR = alpha-adrenergic receptor.

Controls

In order to ensure that detected signal represents specific probe hybridization, several positive and negative controls were performed. Since human nasal turbinate tissue was limited, each probe used in this study was carefully tested in experiments with human spinal cord using antisense human β -actin as a positive control.^{12,13} Negative controls included verifying lack of signal with sense probes and demonstration of loss of signal in known positive samples exposed to excess RNase [*in situ* experiments using excess (50 μ g·mL⁻¹) RNase in washes]. Controls for α AR subtype specificity of antisense probes included simultaneously performed *in situ* experiments with known positive and negative non-nasal turbinate tissues.

Detection and analysis

Due to the thickness of the nasal turbinate specimens, a standard quantitative method previously used in our lab was found to be unreliable.¹³ Instead, relative quantification of mRNA probe hybridization was recorded by two separate blinded observers using the presence of silver grains within specific nasal turbinate specific cell types - epithelium, ducts, glands, and/or vessels. Negative controls included sense probe experiments on the same tissue. Sections were scored by the intensity of silver grain density relative to background (Table I).

Results

There was excellent concordance (> 90%) between the two observers' independent scoring of relative intensities of silver grains for the different nasal turbinate samples. Furthermore, there was no evidence of non-specific signalling in positive control samples. Table II summarizes observations for specific cell types and all α AR subtype mRNAs. While all six AR subtype mRNAs are present in human nasal turbinate,

TABLE II Relative presence of α AR subtype mRNA within human nasal turbinate

| α AR subtype | Epithelium | | | Ducts | | Glands | | Vessels | | |
|---------------------|------------|-----|-----|-------|-----|--------|------|---------|---------------|----|
| | GC | CC | BC | SD | MD | SG | MG | PCV | Sinusoids AVA | |
| α_{1a} | + | 0 | 0 | 0 | 0 | 0 | ++ | 0 | 0 0 | |
| α_{1b} | 0 | + | 0 | + | 0 | ++ | +++ | 0 | 0 | 0 |
| α_{1d} | +++ | +++ | +++ | +++ | +++ | ++++ | ++++ | 0 | 0 0 | |
| α_{2a} | 0 | + | 0 | ++ | + | +++ | + | 0 | 0 | 0 |
| α_{2b} | 0 | + | 0 | ++ | + | +++ | + | 0 | 0 | 0 |
| α_{2c} | + | ++ | +/- | ++ | ++ | +++ | ++ | 0 | ++ | ++ |

Presence of silver granules in cells resulting from *in situ* hybridization of α AR subtype mRNA probes scored by two independent observers. α AR = alpha-adrenergic receptor. Scoring: 0 = silver grain density similar to surrounding background tissue; +/- = very low density of silver grains in darkfield; + = silver grains seen only in darkfield; ++ = moderate density in darkfield, some silver grain apparent with brightfield; +++ = high density in darkfield, groups of silver grains seen in brightfield; ++++ = very high density silver grains in brightfield. GC = goblet cells, CC = ciliated cells, BC = basal cells, SD = serous ducts, MD = mucous ducts, SG = serous glands, MG = mucous glands, PCV = post-capillary venules, AVA = arteriovenous anastomosis.

individual subtype location tends to be restricted to specific cell types (Table II). Representative light and dark field images of nasal turbinate epithelium are presented in Figure 2. In non-vascular tissue, the overall predominant α AR subtype mRNA is the α_{1d} ; this subtype is present in epithelium, ducts and glands. Less generalized presence of other α_1 mRNAs occurs in specific cell types such as goblet cells and mucous glands (α_{1a}) and ciliated cells, serous ducts and glands, and mucous glands (α_{1b}). Within the α_2 AR family, the α_{2c} is present in all epithelial cells, ducts, and glands. In addition, α_{2c} ARs are present in sinusoids and arteriovenous anastomoses, where it is the only α AR present. In contrast, α_{2a} and α_{2b} signal is more restricted.

Discussion

In this study we describe, for the first time, α AR mRNA subtype distribution in ten cell types present in human nasal mucosa. By demonstrating cell and subtype specific expression using *in situ* hybridization, we confirm the hypothesis that α AR subtype distribution in the nasal mucosa is heterogenous. Such findings provide new mechanistic insight regarding potential roles of individual α AR subtypes in human nasal mucosa and suggest more selective targets for nasal decongestion therapy.

In spite of the importance of nasal tissue as a pharmacologic target, little information is available regarding α AR distribution in this tissue. For many years investigators have assumed beneficial effects of α AR

agonists on nasal tissues resulted from vasoconstrictor effects, essentially dampening fluid flow through this tissue.²⁻⁴ Indeed, nasal mucosa is highly vascular. Nasal vessels include arteries and arterioles (resistance vessels), arteriovenous connections, subepithelial and periglandular capillary networks which drain into collecting veins and venous sinusoids (capacitance vessels), and finally the sphenopalatine vein.^{15,16}

Initially investigating α AR effects on vascular tone, Ichimura *et al.*¹⁷ demonstrated the presence of post-synaptic α_1 ARs as well as pre- and postsynaptic α_2 ARs in canine nasal vascular smooth muscles using pharmacologic approaches. These findings suggested that stimulation of either α_1 or α_2 ARs would be expected to provide vascular smooth muscle contraction. Using guinea pig nasal mucosa, Tanimitsu *et al.*¹⁸ suggested that activation of α_{1a} ARs result in contraction of nasal mucosa vasculature. This is in contrast to pharmacologic studies in dogs suggesting both α_1 and α_2 AR mediate vasoconstriction.¹⁹ This disparity between guinea pig and dog in nasal turbinate α AR distribution is not surprising, given the marked species variability in overall expression of AR subtypes, and highlights the importance of studies using human tissue.

Studies in humans suggest the primary mechanism underlying nasal decongestion appears to be venous constriction of the collecting veins and sinusoids,^{15,16,20-23} such constriction decreases engorgement of nasal mucosa, attenuating alterations in nasal anatomy that have been shown to alter nasal




FIGURE 2 Representative examples of *in situ* hybridization experiments in human nasal turbinate tissue. The α_{1d} -antisense probe demonstrates a high density signal by darkfield (A, whitish silver grains in glands, ducts, and epithelial cells) and lightfield (B, black grains) microscopy. High density signal is absent in equivalent experiments in adjacent tissue sections (C and D, respectively) using the α_{1d} -sense (control) probe. Similar experiments using α_{2c} -antisense probe demonstrate more moderate density signal by darkfield (E) and lightfield (F, light brown) microscopy, which is absent in equivalent experiments (G and H, respectively) using the α_{2c} -sense (control) probe. Cell type specificity in α_1 and α_2 signalling is evident in epithelial, duct and glandular regions, and is also visible in vascular tissues at higher levels of magnification (see Table II).

air flow.^{22,24,25} Our results are the first to address this question in humans at an α AR subtype level, revealing presence of only α_{2c} AR mRNA in human nasal sinusoids and arteriovenous anastomoses. In the α AR family, α_2 ARs are primarily responsible for venous (rather than arterial) constriction. This is true for a wide range of venous capacitance beds such as saphenous vein,²⁶⁻²⁸ dermal veins,^{28,29} and nasal mucosa.^{15,16,20,21,30} Our findings suggest an important and unique role for the α_{2c} subtype in nasal sinusoids, making this receptor a new subtype selective target for decongestion.

In addition to sinusoidal constriction as the main mechanism for decongestant action, other mechanisms have been shown to contribute to a lesser extent; such decongestant targets include α_1 AR-mediated arteriolar constriction.^{15,20,30} Andersson and Bende² studied specific α AR effects using topical application of α AR agonists and measurement of Xenon washout in the nasal mucosa of 43 healthy subjects. Findings from this study prompted the authors to conclude that vasoconstrictor actions of phenylephrine are likely due to preferential action on α_1 ARs whereas oxymetazoline action is due to α_2 AR activation.

While vasoconstriction is thought to be the major effect of topical α AR agonists,³ other functional targets are possible. For example, α_1 AR-mediated slowing of nasal ciliary beat frequency,³¹ as well as effects on mucosal gland functioning,³² provides two alternative targets. Alpha AR agonists have been shown to decrease the secretion of serous cell products from human nasal mucosa although underlying mechanisms currently remain unknown.^{2,4} The strong presence of α_{1d} mRNA in epithelial cells, serous, and mucous cells of glands and ducts suggests this adrenergic receptor subtype may play a role in nasal secretions from these cells. Supporting this contention, α_1 AR antagonists (often administered to treat prostate disease) tend to increase nasal secretions.³³ Since the $\alpha_{1a/d}$ selective antagonist tamsulosin also has this effect, this limits the possible subtypes involved to the α_{1a} or α_{1d} . Our demonstration that only α_{1d} mRNA is present on epithelium, ducts, and glands strongly suggests that the α_{1d} AR subtype is important in nasal secretion. This pathway of exocytosis represents a secondary mechanism (beyond simple vasoconstriction) for the efficacy of non-subtype selective α_1 AR agonists currently being marketed as nasal sprays and oral therapies. However, since rhinorrhea is a common side-effect of overuse of oxymetazoline nose sprays, one might hypothesize that avoiding α_{1d} AR effects might minimize this possible complication.

In spite of our novel findings, some limitations to our study exist. Because 10 μ m thick nasal turbinate slices cut through multiple cell layers, precise determination of exact amounts of tissue mRNA was precluded. Instead, we relied on two blinded expert observers; while there was excellent concordance between observers, it should be remembered that our findings represent relative, and not absolute, quantitation. Another possible limitation is that nasal turbinate explants came from patients undergoing functional endoscopic surgery, a surgery often employed for chronic sinusitis. These patients may have been taking medications that may have altered levels of receptor

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.